ABSTRACT
OBJECTIVES: To describe the etiologies of hemoptysis in patients without pre-existing bronchiectasis or cardiac disease; to assess odds of recurrent hemoptysis by diagnostic category; and to assess odds of mortality by diagnostic category. STUDY DESIGN: This retrospective case series included all patients with hemoptysis documented during an admission to Boston Children's Hospital from January 1, 2007 to June 1, 2017. Patients with bronchiectasis, congenital heart disease, primary pulmonary hypertension, bleeding above the glottis, hemoptysis before 38 weeks of corrected gestational age, hematemesis, foreign body, and trauma were excluded. Patients were also characterized by coagulation status. Primary outcomes were recurrent hemoptysis and death. Univariate analysis was performed to determine ORs for recurrence and death per diagnostic category with infection as the reference category. RESULTS: In total, 257 patients met study criteria and were analyzed. The most common causes of hemoptysis were infection (n = 122), neoplasm (n = 58), and other diagnoses (n = 49). Of the patients with infection, recurrence was 28% and all-cause mortality was 12%. Neoplasm had lower odds of recurrence (OR 0.3, P = .012) but higher odds of mortality (OR 15.8, P < .001). Thrombocytopenia had lower odds of recurrence (OR 0.2, P = .005) but higher odds of mortality (OR 5.9, P < .001). Patients with a tracheostomy had higher odds of recurrence (OR 6.3, P < .001), but lower odds of death (OR 0.4, P = .042). CONCLUSIONS: This study confirms that infection is the most common cause of hemoptysis in patients without severe underlying pulmonary or cardiac disease. Hemoptysis associated with neoplasm and/or thrombocytopenia confers mortality risk. Tracheostomy confers risk of recurrence. Future prospective research on diagnoses associated with hemoptysis is warranted.
Subject(s)
Hemoptysis/etiology , Hemoptysis/mortality , Adolescent , Adult , Boston/epidemiology , Bronchiectasis/complications , Child , Child, Preschool , Female , Follow-Up Studies , Heart Diseases/complications , Hemoptysis/diagnosis , Humans , Infant , Infant, Newborn , Logistic Models , Male , Odds Ratio , Recurrence , Retrospective Studies , Risk Assessment , Risk Factors , Young AdultABSTRACT
Dengue fever is an arboviral disease transmitted to humans through the bites of infected female Aedes mosquitoes. Dengue virus is a member of the Flaviviridae family, and human infection can be caused by any of the four antigenically distinct serotypes (DENV 1-4). The infection has become recognized as the most important and prevalent arboviral disease in humans, endemic in almost 100 countries worldwide. Nearly 3 billion people live in areas with transmission risk. Autochthonous transmission of the virus in previously disease-free areas, increased incidence in endemic areas, and epidemic resurgence in controlled regions could increase the risk of contracting more severe forms of the disease, such as dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS). Symptomatic dengue virus infection can present with a wide range of clinical manifestations, from mild fever to life-threatening DSS. Thoracic complications may manifest as pleural effusion, pneumonitis, non-cardiogenic pulmonary edema, and hemorrhage/hemoptysis. No vaccine is currently available and no specific treatment for dengue fever exists, but prevention and prompt management of complications in patients with DHF can help reduce mortality. This review describes the main clinical, pathological, and imaging findings of thoracic involvement in DHF.
Subject(s)
Aedes/virology , Dengue Virus/pathogenicity , Hemoptysis/virology , Lung/virology , Severe Dengue/virology , Animals , Biopsy , Dengue Vaccines/therapeutic use , Diagnosis, Differential , Hemoptysis/diagnosis , Hemoptysis/mortality , Hemoptysis/therapy , Humans , Lung/diagnostic imaging , Lung/pathology , Predictive Value of Tests , Prognosis , Risk Factors , Severe Dengue/diagnosis , Severe Dengue/mortality , Severe Dengue/therapy , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Haemoptysis is a common pathology around the world, occurring with more frequency in low-income countries. It has different etiologies, many of which have infectious characteristics. Antifibrinolytic agents are commonly used to manage bleeding from different sources, but their usefulness in pulmonology is unclear. OBJECTIVES: To evaluate the effectiveness and safety of antifibrinolytic agents in reducing the volume and duration of haemoptysis in adult and paediatric patients. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effects (DARE) in The Cochrane Library, EMBASE and LILACS for publications that describe randomized controlled trials (RCTs) of antifibrinolytic therapy in patients presenting with haemoptysis. We also performed an independent search in MEDLINE for relevant trials not yet included in CENTRAL or DARE. Searches are up to date to the 19th September 2016. We conducted electronic and manual searches of relevant national and international journals. We reviewed the reference lists of included studies to locate relevant randomized controlled trials (RCTs). An additional search was carried out to find unpublished RCTs. SELECTION CRITERIA: We included RCTs designed to evaluate the effectiveness and safety of antifibrinolytic agents in reducing haemoptysis in adult and paediatric patients of both genders presenting with haemoptysis of any etiology and severity. The intervention of interest was the administration of antifibrinolytic agents compared with placebo or no treatment. DATA COLLECTION AND ANALYSIS: All reviewers independently assessed methodological quality and extracted data tables pre-designed for this review. MAIN RESULTS: The electronic literature search identified 1 original study that met the eligibility criteria. One unpublished study was also identified through manual searches. Therefore two randomized controlled trials met the inclusion criteria: Tscheikuna 2002 (via electronic searches) and Ruiz 1994 (via manual searches). Tscheikuna 2002, a double-blind RCT performed in Thailand, evaluated the effectiveness of tranexamic acid (TXA, an antifibrinolytic agent) administered orally in 46 hospital in- and outpatients with haemoptysis of various etiologies. Ruiz 1994, a double-blind RCT performed in Peru, evaluated the effectiveness of intravenous TXA in 24 hospitalised patients presenting with haemoptysis secondary to tuberculosis.Pooled together, results demonstrated a significant reduction in bleeding time between patients receiving TXA and patients receiving placebo with a weighted mean difference (WMD) of -19.47 (95% CI -26.90 to -12.03 hours), but with high heterogeneity (I² = 52%). TXA did not affect remission of haemoptysis evaluated at seven days after the start of treatment. Adverse effects caused by the drug's mechanism of action were not reported. There was no significant difference in the incidence of mild side effects between active and placebo groups (OR 3.13, 95% CI 0.80 to 12.24). AUTHORS' CONCLUSIONS: There is insufficient evidence to judge whether antifibrinolytics should be used to treat haemoptysis from any cause, though limited evidence suggests they may reduce the duration of bleeding.
Subject(s)
Antifibrinolytic Agents/therapeutic use , Hemoptysis/drug therapy , Tranexamic Acid/therapeutic use , Administration, Oral , Adult , Antifibrinolytic Agents/administration & dosage , Hemoptysis/etiology , Hemoptysis/mortality , Humans , Injections, Intravenous , Peru , Randomized Controlled Trials as Topic , Thailand , Tranexamic Acid/administration & dosage , Tuberculosis, Pulmonary/complicationsABSTRACT
BACKGROUND: Haemoptysis is a common pathology around the world, occurring with more frequency in low-income countries. It has different etiologies, many of which have infectious characteristics. Antifibrinolytic agents are commonly used to manage bleeding from different sources, but their usefulness in pulmonology is unclear. OBJECTIVES: To evaluate the effectiveness and safety of antifibrinolytic agents in reducing the volume and duration of haemoptysis in adult and paediatric patients. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effects (DARE) in The Cochrane Library, EMBASE and LILACS for publications that describe randomized controlled trials (RCTs) of antifibrinolytic therapy in patients presenting with haemoptysis. We also performed an independent search in MEDLINE for relevant trials not yet included in CENTRAL or DARE.We conducted electronic and manual searches of relevant national and international journals.We reviewed the reference lists of included studies to locate relevant randomized controlled trials (RCTs). An additional search was carried out to find unpublished RCTs. SELECTION CRITERIA: We included RCTs designed to evaluate the effectiveness and safety of antifibrinolytic agents in reducing haemoptysis in adult and paediatric patients of both genders presenting with haemoptysis of any etiology and severity. The intervention of interest was the administration of antifibrinolytic agents compared with placebo or no treatment. DATA COLLECTION AND ANALYSIS: All reviewers independently assessed methodological quality and extracted data tables pre-designed for this review. MAIN RESULTS: We found two randomized controlled trials which met the inclusion criteria: Tscheikuna 2002 (via electronic searches) and Ruiz 1994 (via manual searches). We did not exclude any of the relevant studies we found.Tscheikuna 2002, a double-blind RCT performed in Thailand, evaluated the effectiveness of tranexamic acid (TXA, an antifibrinolytic agent) administered orally in 46 hospital in- and outpatients with haemoptysis of various etiologies. Ruiz 1994, a double-blind RCT performed in Peru, evaluated the effectiveness of intravenous TXA in 24 hospitalised patients presenting with haemoptysis secondary to tuberculosis.Pooled together, results demonstrated a significant reduction in bleeding time between patients receiving TXA and patients receiving placebo with a weighted mean difference (WMD) of -19.47 (95% CI -26.90 to -12.03 hours), but with high heterogeneity (I² = 52%). TXA did not affect remission of haemoptysis evaluated at seven days after the start of treatment. Adverse effects caused by the drug's mechanism of action were not reported. There was no significant difference in the incidence of mild side effects between active and placebo groups (OR 3.13, 95% CI 0.80 to 12.24). AUTHORS' CONCLUSIONS: There is insufficient evidence to judge whether antifibrinolytics should be used to treat haemoptysis from any cause, though limited evidence suggests they may reduce the duration of bleeding.
Subject(s)
Antifibrinolytic Agents/therapeutic use , Hemoptysis/drug therapy , Tranexamic Acid/therapeutic use , Administration, Oral , Adult , Antifibrinolytic Agents/administration & dosage , Hemoptysis/etiology , Hemoptysis/mortality , Humans , Injections, Intravenous , Peru , Randomized Controlled Trials as Topic , Thailand , Tranexamic Acid/administration & dosageABSTRACT
To determine risk factors associated with fatal hemoptysis (FH) in endobronchial high dose-rate brachytherapy (EHDRB) 84 patients treated with EHDRB from January 1991 to June 2002 were studied. Clinical and technical parameters (including treatment volumes) were analyzed. Eight (9.5%) patients died of FH, all but one with recurrent or persistent local disease. Median interval until death due to FH was 4 months versus 6 months for the whole group. The only factor with significant correlation with FH was the 100% isodose volume (V100) (p=0.04). Larger irradiated volumes were related to FH. Analysis of volume parameters is suggested, together with the dose and number of fractions prescribed for each patient.
Subject(s)
Brachytherapy/adverse effects , Bronchial Neoplasms/radiotherapy , Carcinoma, Non-Small-Cell Lung/radiotherapy , Carcinoma, Small Cell/radiotherapy , Hemoptysis/etiology , Lung Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Female , Hemoptysis/mortality , Humans , Male , Middle Aged , ROC Curve , Radiotherapy Dosage , Retrospective Studies , Risk Factors , Survival AnalysisABSTRACT
Se presenta el análisis de 122 casos de aspergilosis broncopulmonar diagnosticados entre los años 1990 y 1994, en el Departamento de Micología del Instituto Nacional de Higiene y Medicina Tropical de Guayaquil. Todos ellos presentaban anticuerpos frente al antígeno de A. fumigatus demostrables por inmunodifusión por la técnica de Ouchterlony. El estudio micológico en muestras de esputo fue realizado en 60 enfermos. Se señalan los parámetros considerados para el diagnóstico, las lesiones radiológicas observadas y los tratamientos instituídos
Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Adolescent , Adult , Middle Aged , Aspergillus fumigatus/drug effects , Aspergillosis, Allergic Bronchopulmonary/diagnosis , Aspergillus fumigatus/immunology , Aspergillus fumigatus/pathogenicity , Aspergillosis, Allergic Bronchopulmonary/etiology , Aspergillosis, Allergic Bronchopulmonary/drug therapy , Ecuador , Hemoptysis/etiology , Hemoptysis/mortality , Ketoconazole/therapeutic use , Lung Diseases, Fungal/complications , Tuberculosis, Pulmonary/complicationsABSTRACT
Se presenta el análisis de 122 casos de aspergilosis broncopulmonar diagnosticados entre los años 1990 y 1994, en el Departamento de Micología del Instituto Nacional de Higiene y Medicina Tropical de Guayaquil. Todos ellos presentaban anticuerpos frente al antígeno de A. fumigatus demostrables por inmunodifusión por la técnica de Ouchterlony. El estudio micológico en muestras de esputo fue realizado en 60 enfermos. Se señalan los parámetros considerados para el diagnóstico, las lesiones radiológicas observadas y los tratamientos instituídos (AU)
Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Adolescent , Adult , Middle Aged , Aged , Aspergillus fumigatus/drug effects , Aspergillosis, Allergic Bronchopulmonary/diagnosis , Aspergillosis, Allergic Bronchopulmonary/etiology , Aspergillosis, Allergic Bronchopulmonary/drug therapy , Ketoconazole/therapeutic use , Tuberculosis, Pulmonary/complications , Ecuador , Lung Diseases, Fungal/complications , Hemoptysis/etiology , Hemoptysis/mortality , Aspergillus fumigatus/immunology , Aspergillus fumigatus/pathogenicityABSTRACT
A leptospirose humana, uma das principais endemias dos centros urbanos no Brasil, vem crescendo de forma dramática nas três últimas décadas, com prevalência após enchentes causadas pelas chuvas de veräo. Säo descritas as recentes modificaçöes de seus padröes clínicos em nossa regiäo, constituídas pelo surgimento de hemoptise/s maciça/s e da síndrome de angústia respiratória do adulto, ou de ambas associadamente. Essas evidentes mudanças situadas nas estruturas respiratórias depontaram como séria ameaça à vida e como mecanismos de morte, passando a representar entre nós, por sua grande freqüência, a principal causa de óbito na leptospirose. A nova face da doença impöe revisäo dos conceitos sobre sua gravidade e especulaçäo sobre a patogenia dessas alteraçöes. A evoluçäo fatal dos seis pacientes descritos, dois deles sem icterícia e sem insuficiência renal, mostra a grandeza do desafio
Subject(s)
Adult , Middle Aged , Humans , Male , Female , Weil Disease/pathology , Hemoptysis/pathology , Leptospirosis/pathology , Respiratory Distress Syndrome/pathology , Brazil/epidemiology , Cause of Death , Weil Disease/complications , Weil Disease/mortality , Fatal Outcome , Hemoptysis/etiology , Hemoptysis/mortality , Leptospirosis/complications , Leptospirosis/mortality , Respiratory Distress Syndrome/etiology , Respiratory Distress Syndrome/mortalityABSTRACT
Human leptospirosis, one of the main urban endemics/epidemics in Brazil, has dramatically grown in the last three decades, especially after floods caused by summer rains. This presentation describes recent changes in the clinical patterns of this pathology in our region, expressed by the emergence of massive haemoptysis and acute respiratory distress syndrome, or both conditions associated. The evident changes in the respiratory structures emerged as a serious life threat and death mechanisms, becoming the main cause of death in leptospirosis among us because of their high incidence. This new face of the disease demands a revision of current concepts about its seriousness and raises speculations about the pathogenesis of such alterations.
Subject(s)
Hemoptysis/pathology , Leptospirosis/pathology , Respiratory Distress Syndrome/pathology , Weil Disease/pathology , Adult , Brazil/epidemiology , Cause of Death , Fatal Outcome , Female , Hemoptysis/etiology , Hemoptysis/mortality , Humans , Leptospirosis/complications , Leptospirosis/mortality , Male , Middle Aged , Respiratory Distress Syndrome/etiology , Respiratory Distress Syndrome/mortality , Weil Disease/complications , Weil Disease/mortalityABSTRACT
Säo apresentados dois casos de leptospirose com evoluçäo fatal conseqüente a hemorragias pulmonares maciças. O primeiro refere-se a uma paciente jovem que evoluiu sem icterícia ou insuficiência renal e foi a óbito por hemoptises maciças asfixiantes. Os estudos imuno-histológicos de necrópsia confirmaram o diagnóstico de leptospirose. Casos como este, näo eram reconhecidos no passado em nossa regiäo e têm amentado de freqüência, fazendo-nos mudar os conceitos prévios sobre esta patologia. No segundo caso, uma forma clássica da síndrome de Weil na qual a morte foi devida a hemorragia pulmonar severa, o diagnóstico de leptosopirose foi confirmado por sorologia, hemocultivo positivo e estudo necroscópico